Skip to page content
Back to overview

Jan 30, 2024

Peptide agent against multi-resistant bacteria

Life Sciences, Infectious Diseases

  • antibacterial agent for multi drug resistant Gram-negative infections
  • fast action (hours), also bactericidal against non-replicating bacteria
  • especially for patients with autoantibodies against endogenous BPI

Your contact

Dr. Rebecca Kohler

+49 (0) 89 5480177 - 33
Reference Number:


Antimicrobial resistance (AMR) is globally rising over the last decades, partly due to over- or misuse of antibiotics. In 2019, over 3 million deaths were associated with AMR globally. Thereby, the Gram-negative bacteria Escherichia coli, Pseudomonas aeruginosa and Acinetobacter baumannii were within the top six pathogens causing death. Around 8% of patients infected with the aforementioned, resistant pathogens will not survive.


The new peptide-based antimicrobial agent based on an optimized form of the scorpion fish protein BPI (scoBPI) shows very high anti-inflammatory potency towards the endotoxic activity of lipopolysaccharides and a bactericidal activity at nanomolar concentrations against carbapenem-resistant P. aeruginosa, E. coli and A. baumannii. Since the activity of the optimized scoBPI is mediated via membrane perturbation, common resistance mechanisms mediated by e.g. porin loss, efflux pumps and antibiotic-binding or -deactivating proteins do not affect the activity of the antimicrobial peptide.

Commercial Opportunities

  • peptide antibiotic against multi drug resistant gram-negative bacteria
  • especially promising for patients with autoantibodies against endogenous BPI and resulting immunodeficiencies (e.g. in cystic fibrosis, rheumatoid arthritis and systemic lupus erythematodes)

Development Status

Bactericidal activity validated in vitro, in vivo studies ongoing.


  • 1

    Holzinger et al, eLife 12:e86369 (2023)

Interested? Get in touch!

Contact a specific team member via the Team section or simply use our contact form for your request.

Privacy settings

This website uses cookies. Cookies improve its usage and help make this website better.
Privacy policy